D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)

• Status: Unknown status
• Trial end date: 2019-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of chemotherapy combined with dendritic activated cytokine-induced killer cell (D-CIK) for non-small cell lung cancer (NSCLC).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
• Collaborators: Affiliated Cancer Hospital & Institute of Guangzhou Medical University; Affiliated Tumor Hospital of Guangzhou Medical University
• Treatments: Cisplatin; Gemcitabine

Criteria

Inclusion Criteria:

• The patient who have singed the informed consent;

• Histologically confirmed with NSCLC at stage Ⅲb～Ⅳ;

• Expected survival time is more than 2 month;

• Eastern Cooperative Oncology Group (ECOG) performance status was 0-2.

Exclusion Criteria:

• Hemoglobin<8.0 g/dL,White blood cell <3 x 10^9/L;Platelet count <75 x 10^9/L; ALT, AST, BUN and Cr more than normal limits on 3.0 times;

• Known or suspected allergy to the investigational agent or any agent given in association with this trial;

• Pregnant or lactating patients;

• Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection;

• Patients who are suffering from serious autoimmune disease;

• Patients who had used long time or are using immunosuppressant;

• Patients who had active infection;

• Patients who are suffering from serious organ dysfunction;

• Patients who are suffering from other cancer;

• Other situations that the researchers considered unsuitable for this study.